Skip to content
DataLookout
Menu

NCT07682961

Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 148 words Show 4 more changesShow less
    • Primary endpoints: details revised at 1 of 1 entry
    • Enrollment increased: 590 → 850 participants
    • Trial sites expanded: 19 → 61 locations
    • Secondary endpoints: details revised at 3 of 12 entries
  2. Minor Trial sites expanded: 3 → 19 locationsv3
  3. Notable Recruitment opened
    • Trial sites expanded: 0 → 3 locations
    • Start date changed from estimate of Jul 2026 to Jul 14, 2026
    v2
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Proportion of Participants With HIV-1 ribonucleic acid (RNA) ≥ 50 Copies/mL at Week 52 as Defined by the United States (US) Food and Drug Administration (FDA) Snapshot Algorithm.
Timeframe: Week 52

Secondary (12)

Proportion of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 92 as Defined by the US FDA Snapshot Algorithm.
Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 52 as Determined by the US FDA Snapshot Algorithm
Proportion of Participants with HIV-1 RNA < 50 copies/mL at Week 92 as Determined by the US FDA Snapshot Algorithm.
Change From Baseline in clusters of differentiation 4 (CD4) (CD4)+ T-cell Counts at Week 52
Change From Baseline in CD4+ T-cell Counts at Week 92
Show 7 moreShow less
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (AEs)
Percentages of Participants Prematurely Discontinuing Their Study Treatment due to an AE
Trough Concentrations for LEN, TAB, and ZAB at Week 26
Trough Concentrations for LEN, TAB, and ZAB at Week 52
Trough Concentrations for LEN, TAB, and ZAB at Week 104
Percentages of Participants With Antidrug Antibodies (ADAs) and Neutralizing Antibodies (NAbs) of TAB
Percentages of Participants With of ADAs and NAbs of ZAB

Arms and interventions

Treatment Group 1: Lenacapavir(LEN)+ Teropavimab(TAB)+ Zinlirvimab (ZAB)Experimental

Participants meeting susceptibility criteria will receive oral LEN 600 mg, subcutaneous (SC) LEN 927 mg, and intravenously (IV) infusions of TAB and ZAB on Day 1. Participants will self-administer oral LEN 600 mg on Day 2. Every 26 weeks, participants will receive SC LEN and IV infusions of TAB and ZAB up to Week 92. After Week 92, eligible participants will have an option to continue LEN + TAB + ZAB in the extension phase, until completion of the extension phase, permanently discontinuing the extension phase or the extension is discontinued at the sponsor's sole discretion, whichever occurs first.

Treatment Group 2: Cabotegravir (CAB) + Rilpivirine (RPV)Active comparator

Participants who meet susceptibility criteria will discontinue their baseline oral antiretroviral therapy (ART) and will receive intramuscular (IM) CAB 600 mg + RPV 900 mg on Day 1, Week 4 and then every 8 weeks for up to 92 weeks. After Week 92, eligible participants will have an option to continue LEN + TAB + ZAB in the extension phase, until completion of the extension phase, permanently discounting the extension phase or the extension is discontinued at the sponsor's sole discretion, whichever occurs first.

Drugs: Lenacapavir, Lenacapavir Tablet, Teropavimab, Zinlirvimab, Cabotegravir, Rilpivirine

Sites

61 sites in 8 countries

United States 37, Germany 7, South Korea 4, Australia 3, Japan 3, Switzerland 3, Taiwan 3, Spain 1